Title: Swaroop Vakkalanka, et al. Abstract 2704: RP6530, a dual PI3K δ/γ inhibitor, potentiates ruxolitinib activity in the JAK2-V617F mutant erythroleukemia cell lines.
1450824-22-2 | Td 139 | AA01EO2K | MFCD29919388
2137030-98-7 | Ensartinib hydrochloride | AA01EO5X | MFCD31657344
1644545-52-7 | Vorasidenib | AA01EOBQ | MFCD31630835
1673534-76-3 | PD-1-IN-1 | AA01EOGZ | MFCD30738000
1977495-97-8 | Trilaciclib hydrochloride | AA01EON8 | MFCD31630829
1869954-38-0 | [1-(2,2-dimethylpropyl)-1H-indol-3-yl]-2-naphthalenyl-methanone | AA01EOU9
1883548-87-5 | 3-cyclohexyl-6-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-2,4(1H,3H)-pyrimidinedione | AA01EP2P
1383539-73-8 | 4-cyclopentyl-2-[[(2,5-dimethylphenyl)methyl]thio]-1,6-dihydro-6-oxo-5-pyrimidinecarbonitrile | AA01EPCG | MFCD27966183
1673556-40-5 | 4-(aminophenylmethyl)-N-(6-methoxy-2-benzothiazolyl)-benzamide | AA01EPIT
1422355-59-6 | (3β)-3-(3-carboxy-3-methyl-1-oxobutoxy)-N-[1-(4-chlorophenyl)cyclopropyl]-α,21-dioxo-28-norlup-18-ene-17-acetamide | AA01EPOW | MFCD30533317